Evommune, Inc. Other Research and Development Expense
Evommune, Inc. (EVMN) reported Other Research and Development Expense of $9.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-06
- Evommune, Inc. other research and development expense for the quarter ending 2026-06-30 was $9.02M, a 65.37% increase year-over-year.
- Evommune, Inc. other research and development expense for the quarter ending 2026-03-31 was $6.67M, a 64.46% increase year-over-year.
- Evommune, Inc. other research and development expense for the quarter ending 2025-12-31 was $5.88M, a 62.66% increase year-over-year.
- Evommune, Inc. other research and development expense for the quarter ending 2025-09-30 was $4.55M, a 62.16% increase year-over-year.
- Evommune, Inc. other research and development expense for fiscal 2025 was $19.94M, a 93.29% increase from fiscal 2024.
- Evommune, Inc. other research and development expense for fiscal 2024 was $10.31M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.02M 10-Q · filed 2026-08-06 | $15.69M 10-Q · filed 2026-08-06 | $21.57M derived: sum of 3 quarters · filed 2026-08-06 | $26.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.67M 10-Q · filed 2026-05-07 | $12.55M derived: sum of 2 quarters · filed 2026-05-07 | $17.10M derived: sum of 3 quarters · filed 2026-05-07 | $22.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.42M derived: sum of 2 quarters · filed 2026-03-05 | $15.88M derived: sum of 3 quarters · filed 2026-08-06 | $19.94M 10-K · filed 2026-03-05 |
| 2025-09-30 | $4.55M 10-Q · filed 2025-12-11 | $10.00M derived: sum of 2 quarters · filed 2026-08-06 | $14.06M 10-Q · filed 2025-12-11 | $17.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.46M 10-Q · filed 2026-08-06 | $9.51M 10-Q · filed 2026-08-06 | $13.13M derived: sum of 3 quarters · filed 2026-08-06 | $15.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.06M 10-Q · filed 2026-05-07 | $7.67M derived: sum of 2 quarters · filed 2026-05-07 | $10.47M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.42M derived: sum of 2 quarters · filed 2026-03-05 | $10.31M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $2.80M 10-Q · filed 2025-12-11 | $6.70M 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |